The US Federal Trade Commission may take legal action against brandname drug manufacturers who improperly list patents in the US Food and Drug Administration’s Orange Book and factor this behavior in merger reviews.
At their 14 September meeting, the three FTC Commissioners voted unanimously to adopt a policy statement that the agency...